On the public citation graph
Auditing the Producer Price Index: Micro Evidence From Prescription Pharmaceutical Preparations
0 signed · 62 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.2307/1905251openalex-snapshot
Annual Survey of General Economic Theory: The Problem of Index Numbers
inferredcites →https://doi.org/10.2307/1909980openalex-snapshot
Some Observations on the Index Number Problem
inferredcites →https://doi.org/10.3386/w2713openalex-snapshot
The Early History of Price Index Research
inferredcites →https://doi.org/10.3386/w3378openalex-snapshot
Price Indexes for Microcomputers: An Exploratory Study
inferredcites →https://doi.org/10.3386/w3490openalex-snapshot
On the Accuracy of Producer Price Indexes for Pharmaceutical Preparations: An Audit Based on Detailed Firm-Specific Data
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.2339830openalex-extracted
Prices over the Product Life Cycle: Implications for Quality-Adjustment and the Measurement of Inflation
inferred← citeshttps://doi.org/10.2139/ssrn.506224openalex-extracted
Higher Prices from Entry: Pricing of Brand-Name Drugs
inferred← citeshttps://doi.org/10.1002/j.2325-8012.2006.tb00768.xopenalex-snapshot
Assessing Consumer Gains from a Drug Price Control Policy in the United States
inferred← citeshttps://doi.org/10.1007/978-1-4615-0915-8_9openalex-snapshot
THE HEALTH CARE COMPETENCE BLOC: On the Integration of Biotechnology, Pharmaceuticals, and Medical Technologies with Hospital Care and Health Insurance
inferred← citeshttps://doi.org/10.1007/978-1-4615-2219-5_7openalex-snapshot
Regulating Pharmaceutical Prices
inferred← citeshttps://doi.org/10.1007/978-1-4615-5129-4_7openalex-snapshot
Stationarity Tests with Multiple Endogenized Breaks
inferred← citeshttps://doi.org/10.1007/978-94-009-1798-9_8openalex-snapshot
Price and Volume Measures in the System of National Accounts
inferred← citeshttps://doi.org/10.1007/bf01073522openalex-snapshot
Errors of measurement and the recent acceleration in manufacturing productivity growth
inferred← citeshttps://doi.org/10.1016/0167-6296(95)00022-4openalex-snapshot
Price regulation in the pharmaceutical industry: Prescription or placebo?
inferred← citeshttps://doi.org/10.1016/j.energy.2013.06.008openalex-snapshot
Persistence in crude oil spot and futures prices
inferred← citeshttps://doi.org/10.1016/j.enpol.2008.03.018openalex-snapshot
Unit root properties of crude oil spot and futures prices
inferred← citeshttps://doi.org/10.1016/j.healthpol.2010.08.023openalex-snapshot
The impotence of price controls: Failed attempts to constrain pharmaceutical expenditures in Greece
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2012.02.004openalex-snapshot
Pricing of drugs with heterogeneous health insurance coverage
inferred← citeshttps://doi.org/10.1016/s0167-6296(99)00039-9openalex-snapshot
Cross-national price differences for pharmaceuticals: how large, and why?
inferred← citeshttps://doi.org/10.1016/s1574-0064(00)80162-6openalex-snapshot
Chapter 3 Medical care prices and output
inferred← citeshttps://doi.org/10.1017/s1744133111000090openalex-snapshot
Determinants of branded prescription medicine prices in OECD countries
inferred← citeshttps://doi.org/10.1080/000368400404236openalex-snapshot
On the determination of the US aggregate health care expenditure
inferred← citeshttps://doi.org/10.1080/00036840500438954openalex-snapshot
Pricing and patents of HIV/AIDS drugs in developing countries
inferred← citeshttps://doi.org/10.1080/01441649508716917openalex-snapshot
A hedonic price assessment of airline service quality in the US
inferred← citeshttps://doi.org/10.1080/10438590410001629043openalex-snapshot
Zvi Griliches's contributions to the economics of technology and growth
inferred← citeshttps://doi.org/10.1086/378575openalex-snapshot
A Simple Model of Pharmaceutical Price Dynamics
inferred← citeshttps://doi.org/10.1086/426882openalex-snapshot
Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry
inferred← citeshttps://doi.org/10.1097/01.mlr.0000178217.84354.f1openalex-snapshot
Booming Prescription Drug Expenditure
inferred← citeshttps://doi.org/10.1108/03068290310487559openalex-snapshot
The multiple dimensions of mental health services: a conceptual framework
inferred← citeshttps://doi.org/10.1111/1468-0297.00529openalex-snapshot
Empirical Patterns of Firm Growth and R&D Investment: a Quality Ladder Model Interpretation
inferred← citeshttps://doi.org/10.1111/1468-0297.00638openalex-snapshot
Zvi Griliches, 1930–1999: A Critical Appreciation
inferred← citeshttps://doi.org/10.1111/j.1465-7295.1994.tb01310.xopenalex-snapshot
ERRORS IN OUTPUT DEFLATORS REVISITED: UNIT VALUES AND THE PRODUCER PRICE INDEX
inferred← citeshttps://doi.org/10.1111/j.1467-6419.1996.tb00003.xopenalex-snapshot
A SURVEY OF MEASUREMENT BIASES IN PRICE INDEXES
inferred← citeshttps://doi.org/10.1111/j.1477-9552.2002.tb00039.xopenalex-snapshot
Price Variability and Industrial Concentration in U.S. Food Industries
inferred← citeshttps://doi.org/10.1142/s0217590815500873openalex-snapshot
INTERNATIONAL EVIDENCE ON REAL INTEREST RATE PERSISTENCE
inferred← citeshttps://doi.org/10.11606/t.12.2003.tde-12122005-101205openalex-snapshot
Análise econômica dos medicamentos genéricos no Brasil
inferred← citeshttps://doi.org/10.1162/003465397556548openalex-snapshot
The Impact of Computers on Manufacturing Productivity Growth: A Multiple-Indicators, Multiple-Causes Approach
inferred← citeshttps://doi.org/10.1257/jep.7.3.97openalex-snapshot
Pricing, Profits, and Technological Progress in the Pharmaceutical Industry
inferred← citeshttps://doi.org/10.14288/1.0048386openalex-snapshot
Incentives for valued innovation in the pharmaceutical sector : issues for consideration by domestic and international policy makers
inferred← citeshttps://doi.org/10.14302/issn.2574-4526.jddd-24-4996openalex-snapshot
Measuring Quality Change in the Market for Anti-Ulcer Drugs
inferred← citeshttps://doi.org/10.1787/1d002364-enopenalex-snapshot
Measuring consumer inflation in a digital economy
inferred← citeshttps://doi.org/10.1787/9789264028159-enopenalex-snapshot
Handbook on Hedonic Indexes and Quality Adjustments in Price Indexes: Special Application to Information Technology Products
inferred← citeshttps://doi.org/10.19030/iber.v9i7.595openalex-snapshot
Regulating The Pharmaceutical Industry In The European Union: A Dilemma Of Achieving A Single Market
inferred← citeshttps://doi.org/10.1920/wp.ifs.1999.9925openalex-snapshot
Empirical patterns of firm growth and R&D investment: a quality ladder model interpretation
inferred← citeshttps://doi.org/10.20955/r.79.9-42openalex-snapshot
Measuring Consumption: The Post-1973 Slowdown and the Research Issues
inferred← citeshttps://doi.org/10.2165/00019053-199814001-00014openalex-snapshot
International Price Comparisons for Pharmaceuticals
inferred← citeshttps://doi.org/10.22004/ag.econ.25104openalex-snapshot
HIGHER PRICES FROM ENTRY: PRICING OF BRAND-NAME DRUGS
inferred← citeshttps://doi.org/10.2307/2534705openalex-snapshot
Addressing the Quality Change Issue in the Consumer Price Index
inferred← citeshttps://doi.org/10.2307/2534748openalex-snapshot
Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs
inferred← citeshttps://doi.org/10.2307/3350257openalex-snapshot
Toward Allocative Efficiency in the Prescription Drug Industry
inferred← citeshttps://doi.org/10.3233/jem-2001-0201openalex-snapshot
Hedonic indexes and statistical agencies, revisited
inferred← citeshttps://doi.org/10.3386/w11139openalex-snapshot
Assessing Consumer Gains from a Drug Price Control Policy in the U.S.
inferred← citeshttps://doi.org/10.3386/w16014openalex-snapshot
Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
inferred← citeshttps://doi.org/10.3386/w4272openalex-snapshot
Generics and New Goods in Pharmaceutical Price Indexes
inferred← citeshttps://doi.org/10.3386/w6817openalex-snapshot
Price Indexes for Medical Care Goods and Services: An Overview of Measurement Issues
inferred← citeshttps://doi.org/10.3386/w8482openalex-snapshot
Pharmaceutical Prices and Political Activity
inferred← citeshttps://doi.org/10.3406/ecop.1997.5865openalex-snapshot
Une approche hedonique de la formation des prix des médicaments remboursables
inferred← citeshttps://doi.org/10.4337/9781845420529.00014openalex-snapshot
Reassessing the Consumer Price Index: Five Years After the Boskin Commission
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.